Update on the role of quantitative HBsAg and HBeAg monitoring during peginterferon therapy
Current Hepatitis Reports, ISSN: 1540-3416, Vol: 11, Issue: 2, Page: 75-81
2012
- 4Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures4
- Readers4
Article Description
Pegylated Interferon alfa (PEG-IFN) is the only licensed agent that allows a sustained virologic response in a subset group of patients with chronic hepatitis B, both e antigen (HBeAg)-positive and negative, after a finite course of therapy. Despite this major advantage, its use is limited because of its lack of efficacy in a large proportion of patients and a high relapse rate especially in HBeAg-negative patients. Baseline host and viral factors have been largely used to identify candidates for PEG-IFN therapy in the pre-treatment phase, but they have failed to translate into a clear therapeutic choice because of their low predictability. Recently, the use of HBeAg and especially hepatitis B surface antigen (HBsAg) as quantitative serological markers, has led to a revolution in the management of this disease by introducing a new concept of on-treatment prediction of response and stopping rules as early as week 12 of therapy. © 2012 Springer Science+Business Media, LLC.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84865737101&origin=inward; http://dx.doi.org/10.1007/s11901-012-0126-6; http://link.springer.com/10.1007/s11901-012-0126-6; http://www.springerlink.com/index/10.1007/s11901-012-0126-6; http://www.springerlink.com/index/pdf/10.1007/s11901-012-0126-6; https://dx.doi.org/10.1007/s11901-012-0126-6; https://link.springer.com/article/10.1007/s11901-012-0126-6
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know